Medicenna Therapeutics Future Growth
Future criteria checks 2/6
Medicenna Therapeutics is forecast to grow earnings and revenue by 42% and 59.4% per annum respectively while EPS is expected to grow by 40.4% per annum.
Key information
42.0%
Earnings growth rate
40.4%
EPS growth rate
Biotechs earnings growth | 37.2% |
Revenue growth rate | 59.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Feb 2024 |
Recent future growth updates
Recent updates
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully
Oct 18Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
Feb 28Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation
Nov 08Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?
Mar 01We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Aug 07Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?
Apr 14We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Dec 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 15 | -9 | N/A | -15 | 1 |
3/31/2026 | 2 | -19 | N/A | 56 | 3 |
3/31/2025 | 1 | -19 | N/A | 16 | 3 |
3/31/2024 | N/A | -16 | N/A | -16 | 4 |
12/31/2023 | N/A | -15 | -14 | -14 | N/A |
9/30/2023 | N/A | -12 | -13 | -13 | N/A |
6/30/2023 | N/A | -9 | -14 | -14 | N/A |
3/31/2023 | N/A | -10 | -13 | -13 | N/A |
12/31/2022 | N/A | -9 | -13 | -13 | N/A |
9/30/2022 | N/A | -13 | -16 | -16 | N/A |
6/30/2022 | N/A | -20 | -21 | -21 | N/A |
3/31/2022 | N/A | -23 | -24 | -24 | N/A |
12/31/2021 | N/A | -25 | -23 | -23 | N/A |
9/30/2021 | N/A | -26 | -20 | -20 | N/A |
6/30/2021 | N/A | -21 | -17 | -17 | N/A |
3/31/2021 | N/A | -17 | -15 | -15 | N/A |
12/31/2020 | N/A | -14 | -16 | -16 | N/A |
9/30/2020 | N/A | -11 | -14 | -14 | N/A |
6/30/2020 | N/A | -9 | -5 | -5 | N/A |
3/31/2020 | N/A | -8 | -5 | -5 | N/A |
12/31/2019 | N/A | -7 | -5 | -5 | N/A |
9/30/2019 | N/A | -6 | -5 | -5 | N/A |
6/30/2019 | N/A | -5 | -8 | -8 | N/A |
3/31/2019 | N/A | -5 | -8 | -8 | N/A |
12/31/2018 | N/A | -5 | -9 | -9 | N/A |
9/30/2018 | N/A | -5 | -10 | -10 | N/A |
6/30/2018 | N/A | -6 | -11 | -11 | N/A |
3/31/2018 | N/A | -7 | -10 | -10 | N/A |
12/31/2017 | N/A | -11 | -10 | -10 | N/A |
9/30/2017 | N/A | -11 | N/A | -8 | N/A |
6/30/2017 | N/A | -10 | N/A | -8 | N/A |
3/31/2017 | N/A | -8 | N/A | -7 | N/A |
12/31/2016 | N/A | -3 | N/A | -6 | N/A |
9/30/2016 | N/A | -2 | N/A | -5 | N/A |
6/30/2016 | N/A | -1 | N/A | -4 | N/A |
3/31/2016 | N/A | -1 | N/A | -3 | N/A |
3/31/2015 | N/A | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDNA's revenue (59.4% per year) is forecast to grow faster than the Canadian market (6.6% per year).
High Growth Revenue: MDNA's revenue (59.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDNA's Return on Equity is forecast to be high in 3 years time